Intellia Therapeutics, Inc. (NTLA) Stock
3 members of Congress disclosed 13 trades in NTLA since 2017: 6 purchases and 7 sales, most recently Donald Sternoff Beyer (sale, Feb 28, 2022). 7 of the hedge funds AlphaScala tracks reported NTLA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $285.54M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
Which members of Congress traded Intellia Therapeutics, Inc. (NTLA)?
Most recent: Donald Sternoff Beyer (sale, Feb 28, 2022); records start Oct 19, 2017.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Don Beyer D-VA · House | 2022-02-28 | sale | $15k – $50k |
| Don Beyer D-VA · House | 2021-10-29 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2021-09-20 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2021-07-21 | sale | $1k – $15k |
| Don Beyer D-VA · House | 2021-01-15 | sale | $1k – $15k |
| Tom Carper D-DE · Senate | 2020-11-20 | purchase | $1k – $15k |
| Don Beyer D-VA · House | 2020-11-18 | purchase | $1k – $15k |
| Don Beyer D-VA · House | 2020-08-26 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.
See all NTLA political trades →Which hedge funds own NTLA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 16.88M | $285.54M | +16% |
| D.E. Shaw David Shaw | 6.44M | $109.02M | +12% |
| Renaissance Technologies Jim Simons (founder) | 1.40M | $23.69M | NEW |
| Millennium Management Israel Englander | 491K | $8.31M | +596% |
| Point72 Steve Cohen | 398K | $6.74M | +48% |
| Citadel Ken Griffin | 165K | $2.79M | -64% |
| Marshall Wace | 164K | $2.78M | +19% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Intellia Therapeutics, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 2, 26 | Leonard John M | President and CEO | SELL | 9.0K | $108K |
| Oct 2, 26 | Dube Michael P | VP, Chief Accounting Officer | SELL | 1.9K | $23K |
| Aug 21, 26 | Leonard John M | President and CEO | SELL | 2.8K | $36K |
| Aug 20, 26 | Leonard John M | President and CEO | SELL | 19.9K | $251K |
| Jul 22, 26 | Dulac Edward J Iii | EVP, Chief Financial Officer | SELL | 8.1K | $91K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →NTLA price chart
Powered by TradingViewWhat does Intellia Therapeutics, Inc. do?
Intellia Therapeutics is a clinical-stage genome editing company focused on developing curative treatments using CRISPR/Cas9 technology. The company transforms medicine by permanently editing and correcting disease-associated genes within the human body through single-treatment therapies, addressing conditions that were previously untreatable. Intellia's pipeline includes in vivo programs targeting transthyretin amyloidosis and hereditary angioedema, along with proprietary programs developing engineered cell therapies for various cancers and autoimmune diseases. The company operates in the precision genomic medicine space, creating therapies aimed at genetic disorders and oncological conditions. Headquartered in Cambridge, Massachusetts and founded in 2014, Intellia represents a significant player in the evolving biopharmaceutical sector, contributing to next-generation therapeutics and personalized medicine approaches.